Sangamo Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Sangamo Therapeutics

31/10/2023 02:04

* Sangamo Therapeutics Inc  SGMO.OQ   SGMO.O  is expected
to show
a fall in quarterly revenue when it reports  results 
    * The Brisbane California California-based  company is
expected to
report  a 60.7% decrease in revenue to $10.404 million from
$26.46 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Sangamo
Therapeutics Inc
is for a loss of 32 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sangamo
Therapeutics Inc is $6.5​, above​ its last closing price
of $0.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.35       -0.34      -0.66     Missed  -92.7
 Mar. 31 2023  -0.32       -0.33      0.12      Beat    136.6
 Dec. 31 2022  -0.35       -0.36      -0.32     Beat    11.1​
 Sep. 30 2022  -0.34       -0.36      -0.34     Beat    4.3
 ​​Jun.        -0.33       -0.35      -0.29     Beat    17.8
 30 2022                                                
 Mar. 31 2022  -0.31       -0.31      -0.30     Beat    3.5​
 Dec. 31 2021  -0.35       -0.35      -0.26     Beat    24.7
 Sep. 30 2021  -0.34       -0.34      -0.33     Beat    2.1
 This summary was machine generated October 31 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated